These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 35319319)
41. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today? Nagaraj K; Vandenbussche N; Goadsby PJ Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149 [TBL] [Abstract][Full Text] [Related]
42. Novel Medications for the Treatment of Migraine. Ceriani CEJ; Wilhour DA; Silberstein SD Headache; 2019 Oct; 59(9):1597-1608. PubMed ID: 31559638 [TBL] [Abstract][Full Text] [Related]
43. Atogepant for the prevention of episodic migraine in adults. Switzer MP; Robinson JE; Joyner KR; Morgan KW SAGE Open Med; 2022; 10():20503121221128688. PubMed ID: 36226229 [TBL] [Abstract][Full Text] [Related]
44. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Tepper SJ Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405 [TBL] [Abstract][Full Text] [Related]
45. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. Yuan H; Spare NM; Silberstein SD Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020 [TBL] [Abstract][Full Text] [Related]
46. Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine. Blumenfeld AM; Boinpally R; De Abreu Ferreira R; Trugman JM; Dabruzzo B; Ailani J; Lipton RB Headache; 2023 Mar; 63(3):322-332. PubMed ID: 36602199 [TBL] [Abstract][Full Text] [Related]
47. Calcitonin Gene-Related Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta-Analysis. Chan TLH; Cowan RP; Woldeamanuel YW Headache; 2020 Jul; 60(7):1489-1499. PubMed ID: 32515018 [TBL] [Abstract][Full Text] [Related]
48. CGRP inhibitors for migraine prophylaxis: a safety review. Rivera-Mancilla E; Villalón CM; MaassenVanDenBrink A Expert Opin Drug Saf; 2020 Oct; 19(10):1237-1250. PubMed ID: 32811190 [TBL] [Abstract][Full Text] [Related]
49. Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine. Yuan H; White CS; Silberstein SD Clin Pharmacol Ther; 2019 May; 105(5):1121-1129. PubMed ID: 30648737 [TBL] [Abstract][Full Text] [Related]
51. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale. Cohen F; Yuan H; Silberstein SD BioDrugs; 2022 May; 36(3):341-358. PubMed ID: 35476215 [TBL] [Abstract][Full Text] [Related]
52. Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety. Lattanzi S; Trinka E; Altamura C; Del Giovane C; Silvestrini M; Brigo F; Vernieri F Neurol Ther; 2022 Sep; 11(3):1235-1252. PubMed ID: 35705886 [TBL] [Abstract][Full Text] [Related]
53. Erenumab in the treatment of migraine. Jain S; Yuan H; Spare N; Silberstein SD Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976 [TBL] [Abstract][Full Text] [Related]
54. Cardiovascular Disease and Migraine: Are the New Treatments Safe? Robblee J; Harvey LK Curr Pain Headache Rep; 2022 Aug; 26(8):647-655. PubMed ID: 35751798 [TBL] [Abstract][Full Text] [Related]
55. Ubrogepant to treat migraine. Dhir A Drugs Today (Barc); 2020 Jul; 56(7):459-467. PubMed ID: 32648856 [TBL] [Abstract][Full Text] [Related]
56. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine. Maasumi K; Michael RL; Rapoport AM Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205 [TBL] [Abstract][Full Text] [Related]
58. Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis. Ha DK; Kim MJ; Han N; Kwak JH; Baek IH Clin Drug Investig; 2021 Feb; 41(2):119-132. PubMed ID: 33426614 [TBL] [Abstract][Full Text] [Related]
59. The sense of stopping migraine prophylaxis. Al-Hassany L; Lyons HS; Boucherie DM; Farham F; Lange KS; Marschollek K; Onan D; Pensato U; Storch E; Torrente A; Waliszewska-Prosół M; Reuter U; J Headache Pain; 2023 Feb; 24(1):9. PubMed ID: 36792981 [TBL] [Abstract][Full Text] [Related]
60. Pharmacological, Pharmacokinetic, Pharmacodynamic and Physicochemical Characterization of FE 205030: A Potent, Fast Acting, Injectable CGRP Receptor Antagonist for the Treatment of Acute Episodic Migraine. Srinivasan K; Kozminski K; Zhang Y; Wisniewski K; Kohout T; Wisniewska H; Harris G; Lindstrom B; Hargrove D J Pharm Sci; 2022 Jan; 111(1):247-261. PubMed ID: 34217775 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]